Skip to main content

Table 4 Responses to survey questions regarding willingness to participate in clinical trials of various lengths and frequency of visits

From: Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Trial design elements Diagnostic group Likelihood of participation
Very unlikely (score = 1–2) Neutral (score = 3–5) Very likely (score = 6–7)
Annual visits CN 5 (13.5%) 14 (37.8%) 18 (48.7%)
MCI 2 (6.3%) 5 (15.6%) 25 (78.1%)
Dementia 5 (22.7%) 1 (4.6%) 16 (72.7%)
Monthly visits CN 13 (35.1%) 16 (43.2%) 8 (21.6%)
MCI 3 (9.4%) 14 (43.8%) 15 (46.9%)
Dementia 6 (27.3%) 4 (18.2%) 12 (54.6%)
Weekly visits CN 17 (45.9%) 17 (45.9%) 3 (8.1%)
MCI 10 (31.3%) 15 (46.9%) 7 (21.9%)
Dementia 10 (45.5%) 6 (27.3%) 6 (27.3%)
1-year study CN 8 (21.6%) 15 (40.5%) 14 (37.8%)
MCI 3 (9.4%) 11 (34.4%) 18 (56.3%)
Dementia 5 (22.7%) 4 (18.2%) 13 (59.1%)
2-year study CN 7 (20.0%) 19 (54.3%) 9 (25.7%)
MCI 4 (13.8%) 8 (27.6%) 17 (58.6%)
Dementia 5 (25.0%) 3 (15.0%) 12 (60.0%)
5-year study CN 11 (30.6%) 17 (47.2%) 8 (22.2%)
MCI 6 (18.8%) 11 (34.4%) 15 (46.9%)
Dementia 7 (31.8%) 3 (13.6%) 12 (54.6%)
  1. Values are shown as n (%)
  2. CN cognitively normal, MCI mild cognitive impairment